348 filings
ARS
2023 FY
DBVT
DBV Technologies
26 Apr 24
Annual report to shareholders
8:15am
DEF 14A
DBVT
DBV Technologies
Definitive proxy
26 Apr 24
8:13am
PRE 14A
DBVT
DBV Technologies
Preliminary proxy
8 Apr 24
4:35pm
8-K
DBVT
DBV Technologies
8 Mar 24
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
4:05pm
10-K
2023 FY
DBVT
DBV Technologies
Annual report
7 Mar 24
5:25pm
8-K
qlv92di vlnna
7 Mar 24
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
5:17pm
8-K
zcmd7rholx7 io
22 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:05am
S-8
qta2f2
20 Nov 23
Registration of securities for employees
4:06pm
8-K
twakh
9 Nov 23
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
4:52pm
8-K/A
81a32h77u 6c2rcye
6 Nov 23
Departure of Directors or Certain Officers
4:01pm
8-K/A
sucnr6x2lbep1ku
2 Nov 23
Departure of Directors or Certain Officers
8:00am
8-K
j017l
31 Oct 23
Termination of a Material Definitive Agreement
4:54pm
8-K
1ull zw8k9n4b
16 Oct 23
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
4:28pm
8-K
zxiihw
31 Jul 23
Results of Operations and Financial Condition
5:20pm
8-K
4y84go
11 May 23
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
8:27am
8-K
85tg2
4 May 23
DBV Technologies Reports First Quarter 2023 Financial Results
4:43pm
8-K
36jaxody9 f2hzvp
19 Apr 23
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
8:47pm